Phase II randomized study of the IGF-1R pathway modulator AXL1717 compared to docetaxel in patients with previously treated, locally advanced or metastatic non-small cell lung cancer

References

• Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108.
   PubMed Web of Science ®Google Scholar
• Noble J, Ellis PM, Mackay JA, et al. Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline. J Thorac Oncol. 2006;1:1042–1058.
   PubMed Web of Science ®Google Scholar
• Bonomi PD. Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer. 2004;6:154–161.
   PubMedGoogle Scholar
• Scagliotti GV, Novello S. The role of the insulin-like growth factor signaling pathway in non-small cell lung cancer and other solid tumors. Cancer Treat Rev. 2012;38:292–302.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Pan J, Lubet RA, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin for lung cancer chemoprevention. Mol Carcinogen. 2015;54(Suppl 1):E129–37.
   Google Scholar
• Tabernero J, Chawla SP, Kindler H, et al. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab. Target Oncol. 2015;10:65–76.
   PubMed Web of Science ®Google Scholar
• Tran TN, Selinger CI, Yu B, et al. Alterations of insulin-like growth factor-1 receptor gene copy number and protein expression are common in non-small cell lung cancer. J Clin Pathol. 2014;67:985–91.
   PubMed Web of Science ®Google Scholar
• Rosenzweig SA, Atreya HS. Defining the pathway to insulin-like growth factor system targeting in cancer. Biochem Pharmacol. 2010;80:1115–1124.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Dziadziuszko R, Hirsch FR. The rationale and development of therapeutic insulin-like growth factor axis inhibition for lung and other cancers. Clin Lung Cancer. 2009;10:262–272.
   PubMed Web of Science ®Google Scholar
• Girnita A, Girnita L, Del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res. 2004;64:236–242.
   PubMed Web of Science ®Google Scholar
• Ekman S, Frodin JE, Harmenberg J, et al. Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma. Acta Oncol. 2011;50:441–447.
   PubMed Web of Science ®Google Scholar
• Gascoigne KE, Taylor SS. How do anti-mitotic drugs kill cancer cells?. J Cell Sci. 2009;122:2579–2585.
   PubMed Web of Science ®Google Scholar
• King H, Aleksic T, Haluska P, et al. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 2014;40:1096–1105.
   PubMed Web of Science ®Google Scholar
• Fidler MJ, Shersher DD, Borgia JA, et al. Targeting the insulin-like growth factor receptor pathway in lung cancer: problems and pitfalls. Therapeut Adv Med Oncol. 2012;4:51–60.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103.
   PubMed Web of Science ®Google Scholar
• Fossella FV, Devore R, Kerr RN, The TAX 320 Non-Small Cell Lung Cancer Study Group, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol. 2000;18:2354–2362.
   PubMed Web of Science ®Google Scholar
• Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol. 2013;14:981–988.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New Eng J Med. 2015;373:123–135.
   PubMed Web of Science ®Google Scholar
• Kim JS, Kim ES, Liu D, et al. Prognostic implications of tumoral expression of insulin like growth factors 1 and 2 in patients with non-small-cell lung cancer. Clin Lung Cancer. 2014;15:213–221.
   PubMed Web of Science ®Google Scholar
• Agullo-Ortuno MT, Diaz-Garcia CV, Agudo-Lopez A, et al. Relevance of insulin-like growth factor 1 receptor gene expression as a prognostic factor in non-small-cell lung cancer. J Cancer Res Clin Oncol. 2015;141:43–53.
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet. 2009;374:1432–1440.
   PubMed Web of Science ®Google Scholar
• Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–2191.
   PubMed Web of Science ®Google Scholar